BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Putin, Netanyahu discuss Middle East in phone call, Kremlin says - 2The most effective method to Pick the Ideal Lab Precious stone Wedding band
- 3Everything to know about NASA's moon mission launching this week
- 4Pick Your Favored method of transportation
- 5Reconnecting with an old friend is a story of distance, loss and rediscovery
- Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
- Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- Photos: Presidential turkey pardons — a look back
- A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
- Iran War Derails The Automotive Industry
- Top 15 Style Creators Changing the Business
- Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
- Top 20 Compelling Business Books for Progress
